

T\_HSC\_S1PR3\_OE\_UP, XIE\_ST\_HSC\_S1PR3\_OE\_UP

TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION\_HSC\_UP, TONKS\_TARGETS\_OF\_RUNX1\_RUNX1T1\_FUSION\_HSC\_UP  
TAVOR\_CEBPA\_TARGETS\_UP, TAVOR\_CEBPA\_TARGETS\_UP  
VILIMAS\_NOTCH1\_TARGETS\_UP, VILIMAS\_NOTCH1\_TARGETS\_UP  
MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP  
TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_10D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_10D\_UP  
TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_3D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_3D\_UP  
TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP  
MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3, MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3  
JOHNSTONE\_PARVB\_TARGETS\_2\_UP, JOHNSTONE\_PARVB\_TARGETS\_2\_UP  
WINZEN\_DEGRADED\_VIA\_KHSRP, WINZEN\_DEGRADED\_VIA\_KHSRP  
BURTON\_ADIPOGENESIS\_PEAK\_AT\_0HR, BURTON\_ADIPOGENESIS\_PEAK\_AT\_0HR  
GUTIERREZ\_CHRONIC\_LYMPHOCYTIC\_LEUKEMIA\_DN, GUTIERREZ\_CHRONIC\_LYMPHOCYTIC\_LEUKEMIA\_DN  
TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_16D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_16D\_UP  
NAGASHIMA\_EGF\_SIGNALING\_UP, NAGASHIMA\_EGF\_SIGNALING\_UP  
GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7, GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7  
BASSO\_CD40\_SIGNALING\_UP, BASSO\_CD40\_SIGNALING\_UP  
MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP  
BOYLAN\_MULTIPLE\_MYELOMA\_C\_CLUSTER\_DN, BOYLAN\_MULTIPLE\_MYELOMA\_C\_CLUSTER\_DN  
GEISS\_RESPONSE\_TO\_DSRNA\_UP, GEISS\_RESPONSE\_TO\_DSRNA\_UP  
BOYLAN\_MULTIPLE\_MYELOMA\_D\_DN, BOYLAN\_MULTIPLE\_MYELOMA\_D\_DN  
MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP  
BOSCO\_TH1\_CYTOTOXIC\_MODULE, BOSCO\_TH1\_CYTOTOXIC\_MODULE  
KARLSSON\_TGFB1\_TARGETS\_DN, KARLSSON\_TGFB1\_TARGETS\_DN  
SALVADOR\_MARTIN\_PEDIATRIC\_TBD\_ANTI\_TNF\_THERAPY\_NONRESPONDER\_PRE\_TREATMENT\_UP, SALVADOR\_MARTIN\_PEDIATRIC\_TBD\_ANTI\_TNF\_THERAPY\_NONRESPONDER\_PRE\_TREATMENT\_UP  
MIKKELSEN\_MEF\_LCP\_WITH\_H3K4ME3, MIKKELSEN\_MEF\_LCP\_WITH\_H3K4ME3  
LEE\_LIVER\_CANCER\_E2F1\_UP, LEE\_LIVER\_CANCER\_E2F1\_UP  
AMIT\_SERUM\_RESPONSE\_120\_MCF10A, AMIT\_SERUM\_RESPONSE\_120\_MCF10A  
BOYALT\_LIVER\_CANCER\_SUBCLASS\_G5\_DN, BOYALT\_LIVER\_CANCER\_SUBCLASS\_G5\_DN  
DIRMEIER\_LMP1\_RESPONSE\_EARLY, DIRMEIER\_LMP1\_RESPONSE\_EARLY  
ODONNELL\_TARGETS\_OF\_MYC\_AND\_TFRC\_UP, ODONNELL\_TARGETS\_OF\_MYC\_AND\_TFRC\_UP  
LU\_TUMOR\_ANGIOGENESIS\_UP, LU\_TUMOR\_ANGIOGENESIS\_UP  
PEDERSEN\_METASTASIS\_BY\_ERBB2\_ISOFORM\_1, PEDERSEN\_METASTASIS\_BY\_ERBB2\_ISOFORM\_1  
TURASHVILI\_BREAST\_LOBULAR\_CARCINOMA\_VS\_DUCTAL\_NORMAL\_UP, TURASHVILI\_BREAST\_LOBULAR\_CARCINOMA\_VS\_DUCTAL\_NORMAL\_UP  
GESERICK\_TERT\_TARGETS\_DN, GESERICK\_TERT\_TARGETS\_DN  
DAVICIONI\_PAX\_FOXO1\_SIGNATURE\_IN\_ARMS\_DN, DAVICIONI\_PAX\_FOXO1\_SIGNATURE\_IN\_ARMS\_DN  
KHETCHOUMIAN\_TRIM24\_TARGETS\_UP, KHETCHOUMIAN\_TRIM24\_TARGETS\_UP  
ZHAN\_EARLY\_DIFFERENTIATION\_GENES\_DN, ZHAN\_EARLY\_DIFFERENTIATION\_GENES\_DN